Dynamk Capital

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

Vernal Biosciences is an mRNA manufacturing company that offers high-purity mRNA for both research and clinical applications. The company utilizes advanced processing and analytical methods to streamline the manufacturing process, significantly reducing development cycles typical in the advanced therapeutics sector. By providing high-quality mRNA and lipid nanoparticles (LNP-mRNA), Vernal Biosciences enables researchers to conduct drug discovery and development with flexibility, minimizing the need for substantial investment in proprietary teams and facilities. Its services cater to a wide range of mRNA-based life science needs, supporting both animal and human applications.

Vernal Biosciences is an mRNA manufacturing company that offers high-purity mRNA for both research and clinical applications. The company utilizes advanced processing and analytical methods to streamline the manufacturing process, significantly reducing development cycles typical in the advanced therapeutics sector. By providing high-quality mRNA and lipid nanoparticles (LNP-mRNA), Vernal Biosciences enables researchers to conduct drug discovery and development with flexibility, minimizing the need for substantial investment in proprietary teams and facilities. Its services cater to a wide range of mRNA-based life science needs, supporting both animal and human applications.

Bionter operates as a company with the purpose of revolutionizing analytical testing for the benefit of people's health.

Virica Biotech is a biotechnology company focused on enhancing the production and development of viral vector therapeutics to improve human health. The company has developed a Viral Sensitizer technology, which includes a library of over one hundred small molecules. These molecules are designed to safely bypass the body's natural immunological defenses that typically hinder the effectiveness of viral medicines. By utilizing a throughput screening process, Virica identifies these viral sensitizers to aid producers of viral medicine in optimizing their production processes in a cost-effective manner.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Xcell Biosciences, Inc. is a San Francisco-based life science start-up founded in 2012, focused on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a bench-top primary cell control system that captures, grows, and analyzes cancer cells directly from patient blood samples. Their proprietary technology allows for precise control of primary cell phenotype and function, enhancing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences provides researchers with advanced tools for cell maintenance and expansion, ultimately aiming to improve therapy development and clinical outcomes.

Vectron Biosolutions AS specializes in developing and marketing vector technologies for the biotechnology and life sciences sectors. Founded in 2008 and based in Trondheim, Norway, the company provides a range of products including bacterial cloning vectors and expression vectors designed for recombinant protein production in bacteria. Vectron also customizes vectors for specific applications and offers recombinant proteins. Additionally, it delivers services such as protein production, vector design, and molecular engineering, assisting clients in their life science research activities. The company's innovative technology employs an inducible promoter to create bacterial strains that enhance the yield and solubility of therapeutic proteins.

Alpenglow Biosciences is a biotechnology company that specializes in an innovative 3D pathology platform. It offers a sophisticated microscopy imaging system designed to enhance the capabilities of pathologists by enabling nondestructive imaging of large tissue samples in three dimensions at sub-cellular resolution. The company's technology includes patented open-top light-sheet microscopy, along with proprietary sample preparation and cloud-based artificial intelligence analysis software. This comprehensive approach allows healthcare organizations to accelerate drug development processes and improve clinical diagnostics, thereby advancing the overall efficiency and accuracy of pathology.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

RoosterBio, Inc. is a biotechnology company based in Frederick, Maryland, specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine industry. Founded in 2012, RoosterBio focuses on providing human bone marrow-derived and adipose-derived MSCs designed for use by tissue engineers, cell therapists, and developers of technologies that integrate living cells. The company aims to accelerate advancements in regenerative medicine by simplifying and enhancing the research process, thereby enabling high-impact scientific exploration. RoosterBio has established strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc. Through its innovative products, RoosterBio supports efforts to regenerate tissues and organs and addresses immune-related diseases.

RoosterBio, Inc. is a biotechnology company based in Frederick, Maryland, specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine industry. Founded in 2012, RoosterBio focuses on providing human bone marrow-derived and adipose-derived MSCs designed for use by tissue engineers, cell therapists, and developers of technologies that integrate living cells. The company aims to accelerate advancements in regenerative medicine by simplifying and enhancing the research process, thereby enabling high-impact scientific exploration. RoosterBio has established strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc. Through its innovative products, RoosterBio supports efforts to regenerate tissues and organs and addresses immune-related diseases.

FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applications in a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applications in a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com